Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients with Cushing's Disease
Summary
- Eligibility
- for people ages 6-17 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- RECORDATI GROUP
- ID
- NCT03708900
- Phase
- Phase 2 Cushing's Syndrome Research Study
- Study Type
- Interventional
- Participants
- Expecting 12 study participants
- Last Updated